BIOMAT Database Logo BIOMAT Database Logo

Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. 2007

Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.

BACKGROUND Lipodystrophy and dyslipidemia are increasing problems in HIV-infected patients receiving antiretroviral therapy (ART). OBJECTIVE Determine the prevalence and predicting factors for lipodystrophy and dyslipidemia in these patients. METHODS A cross-sectional study was performed on HIV-infected patients receiving ART in January 2006. Clinical assessment for lipodystrophy and blood tests for lipid profile were obtained. RESULTS There were 56 patients with a mean age of 42.3 years and 71.4% were male. Lipodystrophy was detected in 66.1%. Baseline characteristics between patients with and without lipodystrophy were similar except for age, history of receiving d4T and undetectable HIV-RNA (p < 0. 05). There was a high prevalence of dyslipidemia (53.6%). By logistic regression, undetectable HIV-RNA (odds ratio (OR) 6.4, p = 0.016) and receiving d4T (OR 7.4, p = 0.022) are predicting factors for lipodystrophy. CONCLUSIONS Lipodystrophy and dyslipidemia in HIV-infected Thai patients receiving ART are common. Clinical monitoring for these abnormalities during ART is highly recommended.

UI MeSH Term Description Entries
D008060 Lipodystrophy A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy. Lipodystrophies
D008297 Male Males
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013785 Thailand Formerly known as Siam, this is a Southeast Asian nation at the center of the Indochina peninsula. Bangkok is the capital city. Kingdom of Thailand,Siam
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents

Related Publications

Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
External ophthalmoplegia in human immunodeficiency virus-infected patients receiving antiretroviral therapy.
December 2012, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART).
July 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.
September 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
February 2001, Acta virologica,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy.
June 1999, American journal of respiratory and critical care medicine,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
January 2008, Journal of the cardiometabolic syndrome,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy.
April 2008, The American journal of cardiology,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.
May 2002, Archives of pediatrics & adolescent medicine,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
November 2002, Pediatrics,
Yaowaluk Chuapai, and Sasisopin Kiertiburanakul, and Kumthorn Malathum, and Somnuek Sungkanuparph
Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
April 2005, The Pediatric infectious disease journal,
Copied contents to your clipboard!